When Twist Bioscience last reported its March 2025 balance sheet in May 2025, it had zero debt and cash worth US$257m. Importantly, its cash burn was US$65m over the trailing twelve months.

Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities -- Acquisition Will Add In Vivo Antibody Discovery Platform – -- Conference Call at 8:00am ...

Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing ...

A large bioscience employer in South San Francisco has laid off around 25% of its workforce. Twist Bioscience laid off around 270 employees, the San Francisco Business Times first reported.